{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:45:38Z","timestamp":1788867938523,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Children with pediatric inflammatory rheumatic diseases (PRD) have an increased infection risk. Vaccinations are effective to avoid vaccine-preventable diseases. This study aimed to assess the vaccination completeness in Swiss PRD patients stratified by immunosuppressive treatment (IST).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This multicenter observational cohort study of PRD patients was performed in Basel, Geneva, Lucerne, Lausanne, and Zurich in PRD patients aged &amp;lt; 18 years included in the Juvenile Inflammatory Rheumatism Cohort. Completeness was assessed for i) the overall vaccination status (Swiss national immunization program (NIP) and specific additional PRD-recommended vaccinations), ii) for all and each vaccination of the NIP at PRD diagnosis and reference date (RefD) and iii) all and each specific additional PRD-recommended vaccination at RefD. Completeness was assessed over the disease course and stratified by IST.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 616 eligible patients, 234 children were analyzed. Of these, 147 (63%) were girls. Median age at PRD diagnosis was 6.5 years (IQR 2.9\u201310.3) and 10.9 years at RefD (6.9\u201314.3). The median follow-up since PRD diagnosis was 3 years (1.1\u20135.5). 120\/234 children received IST. At RefD, overall vaccination completeness was 3.8% (9\/234 children), completeness for the NIP vaccinations was 70.1% (164\/234 children; IST 65%, no IST: 75.4%) and for all specific additional PRD-recommended vaccinations was 3.8% (9\/234 children; IST 2.5%; no IST 5.3%). Vaccination completeness against pneumococcal disease, hepatitis B virus, and human papilloma virus (HPV) was 50.4, 20, 37.9%, respectively. In 25\/35 children with negative varicella zoster virus history vaccination status was complete (IST: 94.4%, no IST: 47%). Annual non-live influenza vaccination was complete in 24.2% of children during IST; adherence decreased over the disease course.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study identified a low overall vaccination completeness in children with PRD. Particularly, the completeness of specific additional PRD-recommended vaccinations was low. If not performed early after PRD diagnosis, vaccination status remained frequently incomplete. Close collaboration between pediatrician and rheumatologist to improve vaccination completeness is essential. Exchange of vaccination records, standardized assessment of specific PRD-recommended vaccinations and those of the NIP, and annual reminder for influenza vaccination are crucial to improve vaccination completeness in this vulnerable pediatric population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.993811","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T08:31:45Z","timestamp":1662625905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Vaccination completeness in children with rheumatic diseases: A longitudinal, observational multicenter cohort study in Switzerland"],"prefix":"10.3389","volume":"10","author":[{"given":"Tatjana","family":"Welzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Kuemmerle-Deschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Sluka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Carlomagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Cannizzaro Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Hentgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00296-020-04774-3","article-title":"Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: Data from the German BIKER registry.","volume":"41","author":"Thiele","year":"2021","journal-title":"Rheumatol Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acr.22961","article-title":"Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the german biologics in pediatric rheumatology registry.","volume":"69","author":"Becker","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11926-015-0542-z","article-title":"Biologic-associated infections in pediatric rheumatology.","volume":"17","author":"Horneff","year":"2015","journal-title":"Curr Rheumatol Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10067-014-2779-8","article-title":"A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.","volume":"34","author":"Walters","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1586\/14760584.2014.933077","article-title":"Vaccine-preventable diseases in Europe: Where do we stand?","volume":"13","author":"Wicker","year":"2014","journal-title":"Expert Rev Vaccines."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1001\/jama.298.18.2155","article-title":"Vaccine-preventable disease table working g. historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States.","volume":"298","author":"Roush","year":"2007","journal-title":"JAMA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard.2011.150193","article-title":"EULAR recommendations for vaccination in paediatric patients with rheumatic diseases.","volume":"70","author":"Heijstek","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222574","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases.","author":"Jansen","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B10","first-page":"159","article-title":"Impfprinzipien und Empfehlungen f\u00fcr Personen mit autoimmun-entz\u00fcndlichen rheumatischen Erkrankungen.","volume":"8","year":"2014","journal-title":"Buelletin."},{"key":"B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-020-0410-x","article-title":"Maintenance of antibody response to diphtheria\/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.","volume":"18","author":"Brunner","year":"2020","journal-title":"Pediatr Rheumatol Online J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11926-015-0519-y","article-title":"Vaccinations in paediatric rheumatology: An update on current developments.","volume":"17","author":"Groot","year":"2015","journal-title":"Curr Rheumatol Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.autrev.2011.08.010","article-title":"Vaccination in paediatric patients with auto-immune rheumatic diseases: A systemic literature review for the European League against Rheumatism evidence-based recommendations.","volume":"11","author":"Heijstek","year":"2011","journal-title":"Autoimmun Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","article-title":"Impfen bei Immundefizienz : Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie.","volume":"62","author":"Wagner","year":"2019","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.vaccine.2020.01.037","article-title":"Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection.","volume":"38","author":"Uziel","year":"2020","journal-title":"Vaccine."},{"key":"B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12969-018-0231-3","article-title":"Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list.","volume":"16","author":"Speth","year":"2018","journal-title":"Pediatr Rheumatol Online J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-018-0235-z","article-title":"The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: An international survey.","volume":"16","author":"Jeyaratnam","year":"2018","journal-title":"Pediatr Rheumatol Online J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"711637","DOI":"10.3389\/fimmu.2021.711637","article-title":"Vaccination in children with autoimmune disorders and treated with various immunosuppressive regimens: A comprehensive review and practical guide.","volume":"12","author":"Blanchard-Rohner","year":"2021","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00393-007-0150-z","article-title":"[Immunization in children and adolescents with rheumatic diseases].","volume":"66","author":"Minden","year":"2007","journal-title":"Z Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1093\/rheumatology\/kes175","article-title":"Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre.","volume":"51","author":"Morin","year":"2012","journal-title":"Rheumatology."},{"key":"B21","first-page":"164","article-title":"Vaccination coverage in children with rheumatic diseases.","volume":"38","author":"Bizjak","year":"2020","journal-title":"Clin Exp Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e001041","DOI":"10.1136\/rmdopen-2019-001041","article-title":"Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): A systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.","volume":"5","author":"Furer","year":"2019","journal-title":"RMD Open."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.vaccine.2015.01.065","article-title":"Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort.","volume":"33","author":"Hmamouchi","year":"2015","journal-title":"Vaccine."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0153848","DOI":"10.1371\/journal.pone.0153848","article-title":"Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: A retrospective cohort study using data from the clinical practice research datalink.","volume":"11","author":"Costello","year":"2016","journal-title":"PLoS One."},{"key":"B25","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3899\/jrheum.181376","article-title":"Suboptimal immunization coverage among canadian rheumatology patients in routine clinical care.","volume":"47","author":"Qendro","year":"2020","journal-title":"J Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jbspin.2015.11.005","article-title":"Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study.","volume":"83","author":"Brocq","year":"2016","journal-title":"Joint Bone Spine."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/rheumatology\/key120","article-title":"Vaccination coverage in systemic lupus erythematosus-a cross-sectional analysis of the German long-term study (LuLa cohort).","volume":"57","author":"Chehab","year":"2018","journal-title":"Rheumatology."},{"key":"B28","first-page":"1","year":"2016","journal-title":"Schweizerischer Impfplan 2016."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1111\/apa.15275","article-title":"Vaccination coverage of children with chronic diseases is inadequate especially for specifically recommended vaccines.","volume":"109","author":"Diallo","year":"2020","journal-title":"Acta Paediatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1007\/s10067-020-05553-y","article-title":"Suboptimal vaccination coverage of recommended vaccines among French children with recurrent autoinflammatory fever syndromes: A study from the Juvenile inflammatory rheumatism cohort.","volume":"40","author":"Rollet-Cohen","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1097\/RHU.0000000000001251","article-title":"National survey across primary care pediatricians regarding immunization views and practices in children with rheumatic diseases.","volume":"27","author":"Papailiou","year":"2021","journal-title":"J Clin Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12969-016-0095-3","article-title":"Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression.","volume":"14","author":"Leuvenink","year":"2016","journal-title":"Pediatr Rheumatol Online J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00296-012-2426-0","article-title":"Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus.","volume":"33","author":"Lyrio","year":"2013","journal-title":"Rheumatol Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1007\/s10067-021-05836-y","article-title":"Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis.","volume":"40","author":"Potera","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"37817","DOI":"10.1038\/srep37817","article-title":"Effects of annual influenza vaccination on morbidity and mortality in patients with systemic lupus erythematosus: A nationwide cohort study.","volume":"6","author":"Chang","year":"2016","journal-title":"Sci Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00431-020-03751-z","article-title":"Key role of pediatricians and disease for influenza vaccination in children with high-risk chronic diseases.","volume":"180","author":"Alauzet","year":"2021","journal-title":"Eur J Pediatr."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1016\/j.vaccine.2018.06.065","article-title":"Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.","volume":"36","author":"Harrison","year":"2018","journal-title":"Vaccine."},{"key":"B39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00296-021-04817-3","article-title":"Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: A cross-sectional study.","volume":"41","author":"Fragoulis","year":"2021","journal-title":"Rheumatol Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"8138","DOI":"10.1016\/j.vaccine.2018.09.039","article-title":"Influenza vaccination: Uptake and associations in a cross-sectional study of children with special risk medical conditions.","volume":"36","author":"Tuckerman","year":"2018","journal-title":"Vaccine."},{"key":"B41","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1186\/1471-2458-12-984","article-title":"The effect of physician\u2019s recommendation on seasonal influenza immunization in children with chronic diseases.","volume":"12","author":"Pandolfi","year":"2012","journal-title":"BMC Public Health."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.993811\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T08:31:50Z","timestamp":1662625910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.993811\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":41,"alternative-id":["10.3389\/fped.2022.993811"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.993811","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"article-number":"993811"}}